NovaBridge Biosciences (NBP) Current Leases (2019 - 2025)
NovaBridge Biosciences (NBP) reported Current Leases of $891000.0 for Q4 2025, up 9.19% year-over-year from $816000.0 in Q4 2024, and up 2.18% quarter-over-quarter from $872000.0 in Q3 2025.
NovaBridge Biosciences (NBP) Current Leases (2019 - 2025) Analysis & Trends
NovaBridge Biosciences (NBP) has 7 years of Current Leases data on file, last reported at $891000.0 in Q4 2025.
- Current Leases for Q4 2025 came in at $891000.0, up 9.19% year-over-year; the trailing twelve-month figure through Dec 2025 was $891000.0 (up 9.19% YoY), and the FY2025 annual result was $891000.0, up 9.19% from the prior year.
- Current Leases improved to $891000.0 in Q4 2025 per NBP's latest filing, from $872000.0 in the prior quarter.
- Over five years, Current Leases peaked at $4.8 billion in Q4 2021 and troughed at $737000.0 in Q2 2024.
- A 5-year average of $370.8 million and a median of $891000.0 in 2025 frame the typical range for Current Leases.
- The sharpest annual moves came in 2021 and 2022: Current Leases jumped 394417.06% in 2021, then sank 99.93% in 2022.
- A 5-year view of Current Leases shows it stood at $4.8 billion in 2021, then slumped by 99.93% to $3.4 million in 2022, then slipped by 9.76% to $3.0 million in 2023, then tumbled by 73.16% to $816000.0 in 2024, then gained by 9.19% to $891000.0 in 2025.
- Business Quant data shows NBP's Current Leases at $891000.0 in Q4 2025, $872000.0 in Q3 2025, and $853000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | 42,980.09 |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 83,991.00 |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 7.40 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | - |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | NovaBridge Biosciences | 328.19 Mn | 117.34 Mn | - | 891,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 891,000.00 |
| Sep 30, 2025 | 872,000.00 |
| Jun 30, 2025 | 853,000.00 |
| Mar 31, 2025 | 835,000.00 |
| Dec 31, 2024 | 816,000.00 |
| Sep 30, 2024 | 753,000.00 |
| Jun 30, 2024 | 737,000.00 |
| Dec 31, 2023 | 3.04 Mn |
| Jun 30, 2023 | 3.77 Mn |
| Dec 31, 2022 | 3.37 Mn |
| Jun 30, 2022 | 6.35 Mn |
| Dec 31, 2021 | 4.80 Bn |
| Jun 30, 2021 | 1.53 Mn |
| Dec 31, 2020 | 1.22 Mn |
| Sep 30, 2020 | 1.18 Mn |
| Jun 30, 2020 | 1.16 Mn |
| Dec 31, 2019 | 965,782.40 |